Moberg Pharma
36.58 SEK -0.76%3 investors are following this company
Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MOB
Daily low / high price
35.4 / 37.32
SEK
Market cap
1.04B SEK
Turnover
8.21M SEK
Volume
227K
Latest videos
Financial calendar
Interim report
07.05.2024
General meeting
14.05.2024
Interim report
13.08.2024
Interim report
12.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Östersjöstiftelsen | 11.5 % | 11.5 % |
Avanza Pension | 6.4 % | 6.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Moberg Pharma Annual report for 2023
Moberg Pharma: The Nomination Committee's proposal to the Annual General Meeting 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools